APP
MRNA icon

Avantax Planning Partners’s Moderna MRNA Stock Holding History

Avantax Planning Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,040
Closed -$313K – 384
2023
Q1 		$313K Hold
2,040
– – 0.01% 285
2022
Q4 		$366K Buy
+2,040
New +$334K 0.01% 271

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Avantax Planning Partners's MRNA Position: Q2 2023 in Review

Avantax Planning Partners sold out of Moderna (MRNA) in Q2 2023, closing a stake of 2,040 shares — an estimated $313K sold.

Avantax Planning Partners first reported a position in MRNA in Q4 2022 and held it in 2 quarters. The position peaked at $366K in Q4 2022. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Avantax Planning Partners reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Avantax Planning Partners sold 2,040 Moderna shares in Q2 2023, an estimated $313K.
  • Avantax Planning Partners first reported a position in Moderna in Q4 2022 and held it in 2 quarters.
  • Avantax Planning Partners's Moderna position peaked at $366K in Q4 2022.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Avantax Planning Partners's 13F filing for Q2 2023, filed 18 Jul 2023.